Symbol Lookup

Saturday May 25, 2013 10:54 PM ET. Data delayed 15 minutes.
23.21
-0.22 (-0.94%)
Bid/Lots
23.05/1
Ask/Lots
23.21/1
Open/Prev Close
23.05/23.43
Day Range
23.05-23.45
52-Week Range
20.18-27.87
Vol/Avg Daily Vol
153.2K/38.3K
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
Takeda Initiates TOURMALINE-MM2 Pivotal Phase 3 Trial of MLN9708 in Patients with Newly Diagnosed Multiple Myeloma
8:00AM ET on Thursday May 23, 2013 by Business Wire

Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with n...

Lundbeck says drug shows improvement in depression symptoms
1:59PM ET on Saturday May 18, 2013 by Thomson Reuters

COPENHAGEN, May 18 (Reuters) - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III stu...

Takeda And Lundbeck Present Results From Pivotal Phase 3 Clinical Trials With Vortioxetine, An Investigational Compound For Major Depressive Disorder
12:00PM ET on Saturday May 18, 2013 by PR Newswire

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patien...

Takeda Pharmaceutical Company Limited Announces Financial Results for the Fiscal Year Ended March 31, 2013 and Forecasts for the Fiscal Year Ending March 31, 2014
2:08AM ET on Thursday May 09, 2013 by PR Newswire

Takeda Pharmaceutical Company Limited ("Takeda", "the Company") announced today the consolidated financial results for the fiscal year ended March 31, 2013, and forecasts of consolidated results for the fiscal year ending March 31, 2014. The Co...

Takeda to Acquire Inviragen, Inc.
7:00PM ET on Tuesday May 07, 2013 by PR Newswire

Takeda Pharmaceutical Company Limited ("Takeda") and Inviragen, Inc. ("Inviragen") jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for ...

Company Information

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. On September 30, 2011, the Company acquired 100% interests in Nycomed A/S. In January 2012, the Company acquired an America-based company.

CONTACT INFORMATION

HeadquartersTakeda Midosuji Bldg.
4-1-1, Dosho-machi, Chuo-ku
OSAKA-SHI, OSK, Japan 540-8645
Phone--
Fax--

EXECUTIVE OFFICERS

President, Representative DirectorYasuchika Hasegawa
President of Subsidiary, DirectorDeborah Dunsire
Chief Commercial Officer, President of Subsidiary, DirectorFrank Morich
Chief Medical and Scientific Officer, DirectorTadataka Yamada
Managing DirectorYasuhiko Yamanaka

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • Standard & Poor's Stock Report

    Standard & Poor's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap--Beta--
Revenue (TTM)--EPS--
Shares Out.--Book Value--
Dividend Yield4.26%P/E--
Annual Dividend Rate$0.99Price/Sales (TTM)--
Ex-Div Date9/25/12P/Cash Flow (TTM)--
Pay Date12/13/12Operating Margin--

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample